AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer’s disease
Pharmaceutical Investing Denali Therapeutics Announces Reports Full Year 2017 Financial Results And Business Highlights
Pharmaceutical Investing Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency
